NRAS G12V clinical trials at UCSF

1 research study open to eligible people

nras g12v is a change in a cancer gene called NRAS that alters cell signals. UCSF is performing early studies testing a new drug in tumors that have this change. The work tracks safety, dosing, and how the drug acts in the body.

Showing trials for

  • First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors.

    San Francisco, California and other locations

Last updated: